Merger And Acquisition Of Diabetes Drugs And Device Companies: Market Size & Forecast 2026

The M&A market for diabetes drugs and device companies represents the consolidation activity across the full spectrum of diabetes care, including biopharmaceutical manufacturers, medical device producers, and increasingly digital health technology firms. The broader diabetes drugs market is valued at approximately $75.16 billion in 2025 and projected to reach $143.76 billion by 2035, while the diabetes care devices segment grows from $34.30 billion in 2025 to $61.22 billion by 2030 at a 12.3% CAGR, collectively fueling a robust M&A environment. The type 2 diabetes market alone is expected to expand from $40.09 billion in 2025 to $79.25 billion by 2035, reflecting the outsized commercial opportunity that drives acquisition and partnership activity across the industry.

• •The global diabetes drugs market is valued at approximately $75.16 billion in 2025 and projected to reach $143.76 billion by 2035
• •Diabetes care devices market is forecast to grow at a 12.3% CAGR, from $34.30 billion in 2025 to $61.22 billion by 2030
• •The type 2 diabetes market alone is expected to nearly double from $40.09 billion in 2025 to $79.25 billion by 2035

Escalating global diabetes prevalence, projected to affect hundreds of millions of individuals worldwide, creates sustained demand for novel therapeutics and advanced delivery systems, making diabetes-focused companies attractive acquisition targets. The convergence of pharmaceuticals with connected digital health technologies, including continuous glucose monitors, insulin pumps, and companion software platforms, has spurred cross-sector M&A as traditional drug and device companies seek integrated care solutions. Growing emphasis on value-based care models and the need to reduce overall healthcare expenditure are motivating larger entities to acquire companies with proven outcomes data and holistic disease management capabilities.

• •Rising global diabetes prevalence drives sustained demand for novel therapeutics and advanced delivery systems, elevating target company valuations
• •Convergence of pharmaceuticals with digital health technologies stimulates cross-sector dealmaking between drug, device, and software companies
• •Value-based care imperatives and the need for outcomes-driven solutions incentivize consolidation toward integrated diabetes management portfolios

The market encompasses drug classes including insulin, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT2 inhibitors, and other emerging modalities, alongside device categories ranging from traditional blood glucose meters to continuous glucose monitoring systems, insulin pumps, and connected digital platforms. Regionally, North America commands the largest share of M&A activity, buoyed by the United States diabetes market, which reached $31.09 billion in 2025 and is projected to reach $39.80 billion by 2034 at a 2.78% CAGR. Asia-Pacific is emerging as a rapidly growing region for both underlying market expansion and M&A interest, driven by rising disease prevalence, improving healthcare infrastructure, and growing domestic industry capability.

• •Drug segmentation includes insulin, GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT2 inhibitors, while devices span continuous glucose monitors, insulin pumps, and digital health platforms
• •North America leads M&A activity, supported by a U.S. diabetes market growing from $31.09 billion in 2025 to $39.80 billion by 2034 at 2.78% CAGR
• •Asia-Pacific represents the fastest-growing region for both market expansion and M&A interest due to rising prevalence and developing domestic industry capacity

Who are the notable companies in the industry?

The competitive landscape of the diabetes M&A market reflects a moderate-to-highly consolidated structure, shaped by a tiered field of fully integrated multinational healthcare conglomerates and a contingent of specialty producers with narrow therapeutic or technological focus. Technology and process routes span small-molecule synthesis, biologic and peptide manufacturing, miniaturized sensor engineering, and software-driven digital therapeutics development, with leading acquirers pursuing cross-capability breadth to position for portfolio-level value creation. PHC Holdings anchors its positioning in the device and diagnostics tier, pursuing acquisition-led expansion to deepen its footprint across glucose monitoring and metabolic care technologies. Bayer Diabetes Care has historically exemplified the strategic reshaping of diabetes portfolios through divestiture-driven focus, a pattern reflective of broader acquirer behavior in recalibrating segment exposure. Regional capacity remains concentrated in North America and Western Europe, which together command the majority of manufacturing infrastructure and R&D investment, while Asia-Pacific scales rapidly through organic growth and inbound deal activity.

• •The market exhibits moderate-to-high consolidation with integrated multinational players alongside specialty producers focused on specific drug classes or device technologies
• •Core technology routes span peptide and biologic manufacturing for drugs, sensor and electronics engineering for devices, and software development for digital health platforms
• •Manufacturing and R&D capacity remains concentrated in North America and Western Europe, with Asia-Pacific capacity expanding through acquisition and greenfield investment

What are the recent trends and outlook?

The shift toward combination therapies and co-administered drug-device solutions is reshaping M&A priorities, as acquirers seek companies with demonstrated compatibility between pharmacological agents and delivery platforms. Digital therapeutics and AI-assisted drug discovery are creating new M&A frontier categories, with larger companies acquiring software-enabled startups to complement traditional pharmaceutical and device portfolios. The overall outlook remains strongly positive through 2035, supported by an aging global population, expanding type 2 diabetes prevalence in emerging markets, and the ongoing need for companies to build comprehensive, vertically integrated diabetes care offerings capable of competing in value-based reimbursement environments.

• •Combination therapies and co-administered drug-device solutions are driving M&A toward companies capable of delivering integrated treatment platforms
• •Digital therapeutics and AI-enabled drug discovery represent emerging M&A frontiers as incumbents seek to augment traditional portfolios with software capabilities
• •Sustained growth through 2035 is supported by aging demographics, rising type 2 diabetes prevalence in emerging markets, and value-based care mandates